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Abstract
Background: Molecular characterization has contributed to the understanding of the inception,
progression, treatment and prognosis of cancer. Nucleic acid array-based technologies extend
molecular characterization of tumors to thousands of gene products. To effectively discriminate
between tumor sub-types, reliable laboratory techniques and analytic methods are required.
Results: We derived mRNA expression profiles from 21 human tissue samples (eight normal
kidneys and 13 kidney tumors) and two pooled samples using the Affymetrix GeneChip platform.
A panel of ten clustering algorithms combined with four data pre-processing methods identified a
consensus cluster dendrogram in 18 of 40 analyses and of these 16 used a logarithmic
transformation. Within the consensus dendrogram the expression profiles of the samples grouped
according to tissue type; clear cell and chromophobe carcinomas displayed distinctly different gene
expression patterns. By using a rigorous statistical selection based method we identified 355 genes
that showed significant (p < 0.001) gene expression changes in clear cell renal carcinomas
compared to normal kidney. These genes were classified with a tool to conceptualize expression
patterns called "Functional Taxonomy". Each tumor type had a distinct "signature," with a high
number of genes in the categories of Metabolism, Signal Transduction, and Cellular and Matrix
Organization and Adhesion.
Conclusions:  Affymetrix GeneChip profiling differentiated clear cell and chromophobe
carcinomas from one another and from normal kidney cortex. Clustering methods that used
logarithmic transformation of data sets produced dendrograms consistent with the sample biology.
Functional taxonomy provided a practical approach to the interpretation of gene expression data.
Background
Pathologic classification of tumors has been traditionally
based on microscopic appearance. Although morphology
often correlates with natural history of disease, tumors of
a given pattern may have a broad prognostic range and
different responses to treatment. Molecular methods,
such as the evaluation of hormone receptors in breast car-
cinoma, have been effectively employed to further charac-
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terize tumors [1]. Nucleic acid array-based technologies
extend molecular characterization by providing a bio-
chemical snapshot, or profile, of cellular activity that en-
compasses thousands of gene products [2]. Potential
applications beyond diagnosis and prognosis are diverse,
and include treatment response stratification of patients
in clinical trials, assessment of relevance to human safety
of drug-associated tumors in animal carcinogenicity stud-
ies, and the development of more pertinent animal xe-
nograft models of cancer therapy. Successful application
of array-based tools depends on establishing robust labo-
ratory and computational methods that effectively and re-
liably discriminate between tumor types. Recent reports
have demonstrated the power of such tools to distinguish
between clinically meaningful subsets of cancer [3,4].
Renal cell carcinoma (RCCa) represents approximately
3% of all human malignancies with an incidence of 7 per
100,000 individuals. Of these individuals about 40%
present with metastatic disease and a further third will de-
velop distant metastases during the postoperative course.
The most effective therapy for RCCa localized to the kid-
ney is surgery and a metastatic tumor is practically incur-
able. There is a low response to biological modifiers and
the treatment is generally only palliative [5].
We evaluated the RNA expression profiles of renal cell car-
cinomas (RCCa) using the Affymetrix GeneChip plat-
form, comparing mRNA expression profiles from a total
of 21 human tissue samples and two pooled samples. The
21 samples consisted of eight normal kidneys, nine clear
cell carcinomas (CC), two chromophobe carcinomas
(Chr), one urothelial carcinoma and one metanephric ad-
enoma. Expression profiles from a pilot data set of ten
samples were analyzed using multiple clustering algo-
rithms. Genes were then selected from the pilot data set
using a fold-change criteria or from all of the normal and
CC samples using a p-value. Genes that were identified
from both the pilot and the complete data set were cate-
gorized according to a hierarchical classification scheme
based on functional attributes of encoded proteins.
Results
Clustering of the pilot data set
The gene expression data from a pilot data set that consist-
ed of ten samples (patients 1 – 4, consisting of two CC,
two Chr, four normals, two pooled samples) were ana-
lyzed using hierarchical clustering to identify structure
within the data set. Pooled samples were included to de-
termine whether a combined sample yielded an expres-
sion profile representative of the individual samples. To
determine the relatedness of the samples, clustering anal-
ysis was performed. Ten different clustering algorithms us-
ing four methods of pre-processing the data sets were
applied to identify the most consistent sample-clustering
pattern. The rationale behind this approach was to avoid
the bias inherent in any single clustering method and to
determine the most appropriate clustering method for
this data type. Genes that were considered "present"
above background by the Affymetrix software in at least
one of the samples were included in the analyses. This re-
duced the data set to 4571 genes per sample. The 40 sam-
ple clusters were evaluated to see if their dendrograms
fitted the expected sample biology (Table 2). The most
consistent cluster dendrogram, present in 18 of 40 analy-
ses, did indeed match the sample biology (Figure 2A) and
for 16 of these analyses a logarithmic transformation was
used. In the consensus dendrogram, the two CC, two Chr
and four normal samples each clustered in separate
groups. Interestingly, the dendrogram suggested that the
expression pattern of the normal samples was more simi-
lar to the CC than to the Chr samples. As expected, the
pooled normal sample clustered with the normal kidney
samples. The pooled tumor sample clustered more closely
to the CC than to the Chr, possibly due to the greater sim-
ilarity between the two CC, and consequent weighting of
the pooled sample toward the more uniform CC expres-
sion profile.
Clustering of the complete data set
To expand our data set we obtained a further 13 human
tissue samples (patients 12–20), including four normal
kidneys and nine kidney tumors. These were profiled in
the same manner as the first 10 samples. From this com-
bined data set (23 samples) we selected genes classified as
Present (see Methods) at least once (5372 genes) and then
clustered the log-transformed data with average linkage
analysis. This method had previously produced a dendro-
gram that matched the expected sample biology in the pi-
lot data set. The sample dendrogram (Figure 2B) showed
that the relatedness of the samples was similar to that ob-
served with the pilot data set. As seen previously in the pi-
lot data set the normal samples clustered together off a
single node. However the Chr also clustered off this node
and now appeared more similar to normal samples than
CC. The two CC included in the pilot data set (patients 2
and 4) now clustered within a larger CC group that in-
clude the additional CC samples. From this node there
also appeared to be two outlier samples (patients 18 and
20). Pathology reports on these samples revealed that
these were not RCCa samples but instead patient 20 was a
papillary urothelial carcinoma and the sample from pa-
tient 18 was not a carcinoma but a benign metanephric
adenoma.
There were distinct patterns visible in the gene cluster that
were conserved in the CC samples (Figure 2B, zone C), or
the Chr samples (Figure 2B, zone B), or the normal kidney
samples (Figure 2B, zone A). These patterns indicated that
each subtype of tumor expressed a common set of genesBMC Bioinformatics 2002, 3 http://www.biomedcentral.com/1471-2105/3/26
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Figure 1
Histology of tissue samples. Frozen sections of normal kidney with glomerulus in center (A) and clear cell RCCa (B). Rep-
resentative paraffin sections of clear cell (C, E, G) and chromophobe RCCa (D, F, H). Immunohistochemical stains for CD 31
(E and F) and CD 3 (G and H). Note that the clear cell tumor has an the extensive network of CD 31-positive vessels (E) and
numerous scattered CD 3-positive lymphoctyes (G). In contrast, in the chromophobe there is a relative paucity of vessels (F)
and few T cells (H). Original magnification:A, B 100 C – H 200. Staining: A – D, hematoxylin and eosin; E – H, diaminoben-
zidine immunoperoxidase with hematoxylin.BMC Bioinformatics 2002, 3 http://www.biomedcentral.com/1471-2105/3/26
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Figure 2
Sample cluster of the pilot data set (A) and sample and gene cluster of the complete data set (B). The sample
cluster dendrogram form the pilot data set (A) uses the average linkage clustering method and represents the most frequently
occurring dendrogram out of the 40 derived for the data set. Horizontal distance indicates relatedness. The sample and gene
cluster (B) from all 23 samples shows a colored representation of the gene expression data where columns are individual
genes and rows are separate samples. The color in each cell of the table represents the median adjusted expression value of
each gene.BMC Bioinformatics 2002, 3 http://www.biomedcentral.com/1471-2105/3/26
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that could be selected and further characterized. The
urothelial carcinoma and metanephric adenoma ap-
peared to share few of these genes commonly regulated
between the other tissue types.
Functional taxonomy: Genes differentially regulated in CC 
and Chr
To select genes that were changed between CC and Chr in
our pilot data set we used an arbitrary cutoff of 2 fold-
change units in combination with the Affymetrix differ-
ence call (see Methods). Genes were selected according to
criteria described in Table 3, which lists the number of se-
lected genes in each of eight categories. A total of 456
genes were selected by these criteria.
In order to understand the molecular differences between
Chr and CC RCCa on a broader scale, we developed a gene
categorization system ("Functional Taxonomy," see Meth-
ods) in which genes were hierarchically grouped accord-
ing to the cellular function of their protein products. The
number of genes within each primary category was tallied
and plotted to generate a first-level "signature" (Figure
3A). The functional taxonomy signature provided a graph-
ical method to rapidly visualize broad gene expression
characteristics of the tumors. The cellular function catego-
ries that contained the largest number of the 456 genes
were Signal Transduction (97 genes), Cellular and Matrix
Organization and Adhesion (56 genes), Metabolism (54
genes), and Unclassified (65 genes). The CC and Chr sam-
ples demonstrated differences in the numbers or patterns
of increased and decreased genes in these categories and
their subcategories. Almost twice as many genes in Signal
Transduction were increased in CC compared to Chr; a
similar number were decreased in both types. Within Cel-
lular and Matrix Organization and Adhesion, the expres-
sion of nearly four times as many genes was increased in
CC compared to Chr, which decreased expression of
about three times as many genes as did CC. Subcategori-
Table 1: Details of immunohistochemistry
Antibody Type Dilution Source Digestion Detection link
CD 31 Mouse monoclonal 1:20 DAKO Protease 2, 32 min Mouse (Vector)
CD 3 Rabbit polyclonal 1:1000 DAKO Protease 2, 16 min Rabbit (Vector)
Table 2: Summary of 40 sample clusters
Data pre-processing method
Clustering method Unchanged Log10 Transformation Standardization to 
N(0,1)
Log10 transformation and 
Standardization to N(0,1)
Single linkage cluster analysis N Y N N
Average linkage cluster analysis N Y N Y
Complete linkage cluster analysis N Y N Y
Ward's minimum variance cluster analysis N Y N Y
Centroid hierarchical cluster analysis N Y N N
Density linkage cluster analysis N N N N
Flexible-beta cluster analysis N Y N Y
McQuitty's similarity analysis N Y N Y
Oblique principle component clustering, 
correlation P
NY N Y
Oblique principle component clustering, 
correlation S
YY Y Y
Number of methods with cluster 
dendrograms that matched the 
sample biology
19 1 7
"Y" indicates the dendrogram matched the sample biology, "N" indicates it did notBMC Bioinformatics 2002, 3 http://www.biomedcentral.com/1471-2105/3/26
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zation (Figure 3C) revealed a predominance of genes cod-
ing for extracellular matrix proteins (16 genes) and
cellular adhesion molecules (10 genes) that were in-
creased in expression in CC.
Functional taxonomy: Genes differentially regulated in CC
To determine the difference between normal kidney sam-
ples and CC samples we used a rigorous statistical ap-
proach based upon a calculated p-value (see methods)
and the combined data set consisting of eight normal kid-
ney samples and nine CC samples. We identified 142
genes that were significantly upregulated in CC compared
to normal kidneys and 213 that were significantly down
regulated. To determine the biological significance/func-
tion of these genes we used Functional Taxonomy to clas-
sify them into 16 cellular groupings (Figure 4A). The first
level signature showed similar trends to the CC and Chr
comparison (Figure 3A). The four categories that con-
tained the most genes were Signal Transduction (78
genes), Cellular and Matrix Organization and Adhesion
(47 genes), Metabolism (40 genes), and Unclassified (51
genes). These were the same categories that showed the
most gene changes in the pilot data set. Subcategorization
of both categories showed trends within CC samples that
were similar to those observed in the pilot data set. Within
the Signal Transduction category there were many genes
associated with ligands, receptors and cytosolic factors
(Figure 4B and Table 4). Gene expression changes within
the Cellular Matrix Organization and Adhesion category
were focused on extracellular matrix genes and cellular ad-
hesion molecules (Figure 4C and Table 5).
Immunohistochemistry
The selected gene lists were reviewed for genes that corre-
sponded to proteins that could be evaluated with immu-
nohistochemistry. The data sets revealed that mRNA
transcripts for CD 31 (PECAM) and the T-cell receptor
beta chain were increased in CC but not Chr. Since anti-
bodies to CD 31 and CD 3 (which forms a complex with
the T cell receptor) are reactive in fixed tissues, we used
them to stain the tumors. CD 31 was present in CC in a
prominent dense branching network of fine vessels sur-
rounding the tumor cells (Figure 1E). In contrast, Chr had
few CD 31-positive vessels present (Figure 1F). CD 3
stained numerous T lymphocytes scattered throughout
the CC tumors (Figure 1G). These were not initially appar-
ent in the hematoxylin and eosin sections, probably due
to the similarity in size and appearance of the tumor cell
nuclei and the lymphocytes. In contrast, there were almost
no T cells in the Chr tumors (Figure 1H). These results in-
dicated concordance between the mRNA expression pro-
files and the pathobiology of the RCCa tumor sub-types.
Discussion
Expression profiling of kidney tumors using the Affyme-
trix GeneChip distinctly separated four different tumors
from each other, as well as from normal kidney cortex.
This finding is consistent with the morphologic, karyotyp-
ic and clinical outcome differences between these tumor
types [6,7]. There are many sample-clustering methods
that may be applied to expression microarray data, none
of which can be conclusively called "correct", since each
algorithm makes different assumptions regarding the na-
ture of the data. We used ten clustering methods com-
bined with four ways of pre-processing the data sets to
eliminate, or at least reduce bias in a pilot data set. The
smaller pilot data set was used to simplify the interpreta-
tion of the results. A common cluster dendrogram was
produced by 18 of 40 methods; 16 of these were from the
20 that employed logarithmic transformation of the data
sets. The pattern was consistent with the biology of the
sample with normal kidney, CC and Chr samples each
grouping together (Figure 2A). That a logarithmic trans-
formation gave the most meaningful cluster dendrograms
Table 3: Number of selected genes in each category from pilot data set
Selection criteriona
Number of genes
Increase in all tumors 10
Decrease in all tumors 59
Increase in Chr 76
Decrease in Chr 99
Increase in CC 136
Decrease in CC 40
Diametric discriminator 1 (increase in Chr, decrease in CC) 13
Diametric discriminator 2 (increase in CC, decrease in Chr) 23
Total 456
aGene selection based on two fold-change threshold in tumor relative to normal.BMC Bioinformatics 2002, 3 http://www.biomedcentral.com/1471-2105/3/26
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Figure 3
Functional taxonomy signatures of clear cell and chromophobe RCCa. The 456 genes that were selected according
to the criteria in Table 3 were annotated and placed into 16 cellular function categories (A). The number of genes in each cel-
lular function category is displayed. A positive value indicates the genes were increased in expression while a negative value
indicates the genes were decreased in expression. The second-level signatures for the subcategories of Signal Transduction,
and of Cellular and Matrix Organization and Adhesion are shown in panels (B) and (C) respectively.BMC Bioinformatics 2002, 3 http://www.biomedcentral.com/1471-2105/3/26
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Figure 4
Functional taxonomy signatures of clear cell RCCa. The 355 genes that were selected from the complete data set were
annotated and placed into 16 cellular function categories (A). The number of genes in each cellular function category is dis-
played. A positive value indicates the genes were increased in expression while a negative value indicates the genes were
decreased in expression. The second-level signatures for the subcategories of Signal Transduction, and of Cellular and Matrix
Organization and Adhesion are shown in panels (B) and (C) respectively.BMC Bioinformatics 2002, 3 http://www.biomedcentral.com/1471-2105/3/26
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is consistent with the distribution of the untransformed
expression data being skewed to the left because the ma-
jority of genes have low expression levels. Standardization
of the data assigns equal weight to each gene and, hence,
increases the contribution of unreliable low expression
genes. The use of logarithmic transformation, on the other
hand, improves the spread of the data so the distribution
is close to normal. It also re-adjusts the weight for each
gene. For example, genes with high expression levels,
which might be unreliable or biased due to saturation,
will have lower weights in distance calculation. Therefore,
the logarithmic transformation improves the calculation
of distance for the subsequential clustering algorithms
and leads to uncovering the biological meaningful pattern
within the data.
A comparison of the dendrograms from the pilot data set
and complete data set reveals some surprising changes. In
general the major structure of the dendrogram remained
the same, CC, Chr and normal kidney all grouped sepa-
rately. However, in the pilot data set the CC were more
similar to normal kidney than Chr, while in the complete
data set Chr were more similar to normal kidney. It is un-
clear why this larger data set changed the dendrogram and
suggests that the subtle structure in the dendrogram was
not as robust as it appeared. With fewer Chr compared to
Table 4: Signal Transduction
Ligand Receptor Receptor binding 
protein
Cytosolic factor Nuclear factor Other signaling 
activities
Increased in CC TNFSF7 CXCR4 IGFBP3 HPCAL1 IFI16 LCP2
VEGF FCER1G SHC1 INHBB
SCYA5 IFNGR1 NCK1 PTPN12
TGFB1 CSF1R CBLB
SELPLG LY117 GNAI2
IFNAR2 HCLS1
TNFRSF1A GUCY1B3
C3AR1 ARHGEF6
CD3D ADCY7
CD14 MTAP44*
TNFRSF6 GIT2
LGALS9 ARHGDIB
RRAD
HCK
GBP2
PTPNS1
NMI
PRKCL1
ANXA1
PPP1CC
RASA3*
RIT
Decreased in CC EGF NR3C2 GRB7 M1S1 FOXI1
FGF1 FGFR3 TRAF4 RAP1GA1 HOXB3
FGF9 GABRA3 GNA11
SEMA3B PTGER3 PVALB
NPY1R PRKCZ
PCDH1 PPP2CB
GPC3 APLP2
PDGFRA ANXA11
EPOR RALBP1
CASR CRABP2
FOLR1 GPS1
ERBB2 PDE1A
NR2F6 BCR
* Not an approved HUGO nameBMC Bioinformatics 2002, 3 http://www.biomedcentral.com/1471-2105/3/26
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CC it is not possible to draw any strong conclusions about
relatedness of the Chr samples.
In order to visualize the functional patterns associated
with a particular set of selected genes we used a simple,
semi-hierarchical system to categorize genes according to
the function of the proteins they encode, that we call
Functional Taxonomy. There are challenges associated
with the partly subjective nature of categorization of gene
function, such as where to place a single gene product that
is involved in several cellular tasks. Ideally, the categoriza-
tion should consider multiple attributes of a protein. To
this end, we propose three complementary classification
schemes: (1) biochemical function, which categorizes ac-
cording to molecular activity; (2) cellular function, which
categorizes according to biological role at a cellular level;
(3) tissue function, which categorizes according to ana-
tomic or organ system location. In this paper we have vis-
ualized profiling results using the second of these schemes
(cellular function) at three levels: primary categories, sec-
ondary categories, and individual genes (see Figure 3 and
4, Table 4 and 5). We have found Functional Taxonomy
to be a useful visualization tool for understanding the dif-
ferences in gene expression patterns between CC and Chr
tumors. This system is similar in concept to what is cur-
rently being developed by the Gene Ontology Consorti-
um [10].
The cellular function signatures of nine CC and two Chr
revealed that the greatest number of gene expression
changes for both tumor types occurred in the categories of
Signal Transduction, Cellular and Matrix Organization
and Adhesion, and Metabolism. This is consistent with
current theories of neoplasia, which hypothesize that tu-
mor cells modify their signaling pathways, establish new
contacts with an altered extracellular matrix, and refash-
ion their metabolic machinery.
There exists considerable literature on the expressed genes
and gene products associated with RCCa. Using the select-
ed gene sets from Table 3 and the p-values and fold-
change values calculated from the eight normal kidneys
and nine CC, we looked for concordance between our re-
sults and published reports. The genes CA 9 (carbonic an-
hydrase IX),  CCND1 ( cyclin D1),  CDH2 ( N-Cadherin),
EGFR (epidermal growth factor receptor) and TGFA (tran-
forming growth factor alpha) all showed increases in CC ex-
pression that matched the literature and had p-values 
0.0061 [11–15]. The observed decrease in CDH1 (E-cad-
herin) in CC (p-value = 0.0045) also matched previously
published reports, as did the decrease in VIM (vimentin)
expression in Chr RCCa [13,16]. VIM was also found to be
increased in CC with a p-value = 0.0045, which was con-
sistent with the literature. We detected a small increase in
expression of ICAM1 (intercellular adhesion molecule 1) in
CC (Fold-change = 1.9, p-value = 0.0081), which was also
consistent with the literature [17].
The expression results for the genes JUN (c-jun) and VHL
(von Hippel-Lindau) did not match the literature [18,19].
Nor did the result for KRT7 (cytokeratin 7), which has been
shown to be overexpressed in Chr [20]. Instead we found
KRT7 to be strongly repressed in CC (fold-change = -5.1,
p-value = 0.0009). Yet, expression profiling using nucleic
acid microarrays does not necessarily correlate with other
forms of analysis for all genes [21,22]. This may be espe-
cially true when altered expression of a gene is reported to
be present in a subset of a population of tumors, since a
small sample number (as are the Chr samples in this
study) may not include the alteration.
In the case of CD 31 and the T cell receptor beta chain, ex-
pression profiling results were concordant with immuno-
histochemical analysis of the tumors. The prevalence of
the scattered T cells within the CC tumors was somewhat
surprising, but entirely consistent with the biology of re-
sponse to a treatment for RCCa, interleukin 2 (IL-2), since
IL-2 activates lymphocytes against the tumor [23].
During preparation of this manuscript, an expression pro-
filing study of seven renal neoplasms (four CC, 2 oncocy-
tomas, and one Chr) was reported [24]. This study
employed a different platform (Incyte glass slide cDNA
microarray) and hybridization method (competitive tu-
mor/normal binding), and used related but not identical
gene selection criteria (two fold-change in expression ver-
sus normal kidney in at least two of the seven tumors).
The study identified 189 genes that were differentially ex-
pressed in at least two tumors, and this gene set was also
able to distinguish between CC and Chr tumor types. We
suspect that a greater number of Chr-associated genes
would have been selected in their study had there been at
least two Chr samples, since a gene altered in expression
only in the single Chr, but not in any of the oncocytomas
or the CC, would not have been identified by the selection
criteria.
Conclusion
The results of the present study demonstrate the power of
Affymetrix GeneChip expression profiling to differentiate
between morphologically distinct tissues that are de-
scended from a common organ. In addition, they demon-
strate the value of functional cataloging selected genes and
visualizing the result in a graphical format.
Methods
Sample isolation, histology and immunohistochemistry
Renal cell carcinoma (RCCa) samples were collected from
patients undergoing radical nephrectomy at the Universi-
ty of Michigan Medical Center. All samples and associatedBMC Bioinformatics 2002, 3 http://www.biomedcentral.com/1471-2105/3/26
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clinical data were obtained with Institutional Review
Board approval. A total of 21 tissue samples (eight normal
kidneys and 13 tumors) were obtained from 13 patients.
Patients ranged in age from 40 to 83 years with four male
patients and nine female patients. Nine patients were di-
agnosed with clear cell carcinomas (CC), two with
chromophobe cell carcinomas (Chr), one with a papillary
urothelial carcinoma, and one with a metanephric adeno-
ma. For eight of the patients the resection specimens in-
cluded unaffected kidney (termed "normal kidney") as
well as tumor tissue. Tissue samples were fixed in forma-
lin, or were immediately frozen at -80C in optimal cut-
ting temperature embedding medium (OCT, Sakura).
Cryostat sections were prepared to confirm suitability for
profiling (Figure 1A and 1B); only viable-appearing tis-
sues were processed. Care was taken to ensure that normal
tissue was not contaminated with tumor tissue and vice
versa. Normal kidney samples were uniformly taken from
renal cortex. Paraffin-embedded tissues were stained with
hematoxylin and eosin for diagnostic evaluation. Repre-
sentative morphologies are shown in Figure 1C and 1D.
Immunohistochemical stains were performed on fixed tis-
sues. Sections were deparaffinized, rehydrated and treated
with 3% hydrogen peroxide. Stains were performed using
an automated avidin-biotin complex method according
to the manufacturer's protocol (Nexes IHC Staining Sys-
tem, Ventana Medical Systems), with details as indicated
in Table 1.
RNA isolation
Total RNA was prepared from each sample (eight normal
kidneys, 13 tumors). In addition, two pooled samples
were made by mixing equal quantities of RNA from the
kidney samples of patients 1 – 4 together, and by mixing
equal quantities of RNA from the four RCCa samples also
from patients 1 – 4. The frozen tissues were warmed brief-
ly, allowing the OCT compound to soften slightly so that
it could be rapidly dissected away without the tissues
thawing. The tissues were then pulverized using a frozen
steel block and hammer. RNA was extracted using Trizol
reagent (Life Technologies) according to the manufactur-
er's protocol.
RNA labeling and GeneChip hybridization
Biotinylated target RNA was prepared from 15 g of total
RNA using the Affymetrix protocol. Labeled cRNA was hy-
bridized on the HuGeneFL Affymetrix GeneChip® con-
taining probes for approximately 5600 mRNAs
corresponding to genes of known sequence. Each hybrid-
ization included control RNA transcripts. The hybridiza-
tion reactions were processed and scanned according to
standard Affymetrix protocols.
Data Analysis
The Affymetrix Microarray Suite and Data Mining Tool
were used to calculate average difference (gene expres-
sion) values, fold-change values and difference calls from
Table 5: Cellular and matrix organization and adhesion
Extra cellular 
matrix
Inner membrane 
organization
Organization of 
the cytoskeleton
Organization 
of the plasma 
membrane
Cellular 
adhesion 
molecules
Organization of 
muscle fibers
Increased in CC P4HA1 CAV2 LCP1 SPARC
COL4A2 TMSB10 ITGAM
COL1A1 TUBB PECAM1
PLOD2 LAMA4
CAV1 ITGA5
COL1A1 GJA1
COL1A2 CLECSF2
P4HB ITGB2
PLOD TGFBI
COL4A1
SERPINB1
FN1
Decreased in CC APM1* PTPN3 PFN2 PALM TM4SF3 MYL6
MFAP4 ABLIM CLDN10 TNNC1
HYAL1 KRT7 PLXNB1 MYH10
LAD1 ARHGEF5 MUC1 ADF*
LLGL2 TACSTD1
LU
CDH1
* Not an approved HUGO nameBMC Bioinformatics 2002, 3 http://www.biomedcentral.com/1471-2105/3/26
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the GeneChip fluorescent intensity data. All GeneChips
were normalized to avoid differences in fluorescent inten-
sity as described in the Affymetrix GeneChip Expression
Analysis Manual (version 3.1). The average intensity of each
gene chip was scaled to 600, where average intensity was
calculated by averaging all the gene expression values of
every probe set on the array excluding the highest and
lowest 2% of the values. If the scaling factor did not fall
between 0.3 and 2, the GeneChip data was not used. Fold-
change values were calculated as the ratio of gene expres-
sion values between each tumor-normal sample pair from
the same patient, with the normal sample values used as
the baseline. The difference call was calculated using four
variables: the number of probes pairs that have changed
in a certain direction, the ratio of increased probe pairs
over decreased probe pairs, the log average ratio change,
and the difference in the number of probe pairs changed
(either positive or negative). The default values (explained
in the Affymetrix Manual) were used in the difference call
decision matrix. The resulting data sets were manipulated
and filtered in Microsoft Access according to various crite-
ria (see results) for selection of genes that showed altered
expression in the tumors.
For the pilot data set, sample clusters were prepared using
the software program SAS (SAS Institute, Cary, NC) on the
gene expression values. The following clustering algo-
rithms were used: seven hierarchical clustering methods
(single linkage, average linkage, complete linkage, Ward's
minimum variance, density linkage, centroid, and flexi-
ble-beta), a k-mean method, and an oblique principle
component method employing either (1) Pearson corre-
lation or (2) Spearman correlation based on rank. Nega-
tive values were set equal to one. Data sets were processed
as follows for the clustering analysis: unchanged (raw da-
ta), log10 transformation, standardization to N(0,1), and
a combination of both log10 transformation and stand-
ardization to N(0,1). This yielded a total of 40 sample
cluster dendrograms. For the complete data set (21 sam-
ples plus two pooled samples) gene and sample clusters
were prepared using Cluster and visualized with TreeView
[25], using log10-transformed and median-centered aver-
age difference values.
To select genes for further analysis from the pilot data set,
a two fold-change threshold was used in combination
with the Affymetrix difference call of either increase (I),
marginal increase (MI), decrease (D) and marginal de-
crease (MD). For genes selected as either increased or de-
creased in a particular RCCa subtype both samples had to
show concordance in their fold-change and difference
call, and both samples from the other subtype had to have
a difference call of no change (NC) or a call that was op-
posite to that of the first subtype.
To select genes that were significantly changed in CC
(nine samples) verses normal kidney (eight samples) a
non-parametric Wilcoxon test was used to calculate a p-
value for each gene. Genes were then selected that con-
formed to all of the following criteria: p-value  0.001; a
mean average difference value  200; fold-change  1.1 for
genes increased in CC relative to normal kidney or fold-
change  -1.1 for genes decreased in CC relative to normal
kidney.
All selected genes were then annotated using online re-
sources, such as Medline, OMIM and GeneCards. The in-
formation was used to build a database that included
HUGO (Human Genome Organization) designated
names, function and expression information, and any tu-
mor associations.
Given the absence of available tools for visualization of
tumor gene expression patterns on a broad scale, we de-
vised a classification system called "Functional Taxono-
my" that categorizes genes according to various functional
attributes of the proteins they encode. One such function-
al attribute is a protein's biological role at a cellular level.
Using a mammalian modification of the MIPS Saccharo-
myces cerevisiae functional categories [26], (Munich Infor-
mation Center for Protein Sequences,
[www.mips.biochem.mpg.de]) the genes were placed into
a hierarchical classification scheme containing 16 primary
categories of cellular function. The number of genes that
fell within each primary category was counted and plotted
graphically to generate a first-level "signature" (see Figure
3A and 4A). Each of the primary categories was further di-
vided into subcategories for a more detailed second-level
visualization of the data (see Figures 3B, 3C, 4B and 4C).
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